Sanjay Bambhaniya · May 20, 2026

Bio Medica Laboratories SME IPO Review | APPLY or AVOID?

SME Book Build Listed

Pharmaceutical

NSE SME

Price Band

₹132 - ₹139

Issue Size

₹52.43 Cr.

Lot Size

1000 Share

Min. Investment

₹1,39,000

Live GMP ₹0

0.00% Est. Listing: ₹139

SIP Calc Compare

IPO Timeline

DRHP FILED May 21, 2026

OPEN May 21, 2026

CLOSE May 25, 2026

ALLOTMENT May 26, 2026

LISTING May 29, 2026

IPO DETAILS REVIEW GMP SUBSCRIPTION ALLOTMENT STATUS

Bio Medica Laboratories started in 2015. It operates in the Pharmaceutical industry and provides pharmaceutical parenteral formulations to its customers across human and veterinary fields. This business is based in Indore. This IPO review covers the main facts of the offer. It helps you decide if the issue fits your portfolio.
Bio Medica Laboratories Ltd. shows rapid growth but the sustainability of boosted margins remains a key point to consider investors. The company operates in a highly competitive sector, and its sudden profit jump raises serious doubts.

✅ Strengths

Specialized injectable product portfolio
Essential regulatory quality certifications
Robust recent financial growth
Strong operating profit margins
Established B2B business model
Experienced pharma promoter team
Government backed incentive benefits
Advanced internal laboratory equipment

⚠️ Challenges

Severe client concentration risk
Heavy debt financial burden
Leased manufacturing plant dependency
Past regulatory unit suspensions
Highly competitive & fragmented market segment
Aggressive public issue pricing
No internal research department
Promoter share cost zero

Financial Update

The company released its restated financial statements for the year ending March 31, 2025. Total revenue was ₹38.33 crore increased from ₹15.34 crore in previous year. The net profit for the same period was ₹9.50 crore increased from ₹2.50 crore in previous year. The business earned a net profit of ₹0.33 crore on a total income of ₹16.25 crore during FY23. The total income rose to ₹28.63 crore during the eight month period ending November 30, 2025. The net profit reached ₹8.66 crore during this same eight month period. The net profit margins grew significantly from 2.06% in FY23 to 30.35% in the latest eight month period. This trend should be carefully studied prior to any investment.

IPO Valuation

The upper price band is ₹139. This price leads to a Price-to-Earnings (P/E) ratio of 17.84 based on FY25 earnings. The average P/E for the industry is -. The public issue price shows a P/E ratio of 13.46 if we calculate it using the annualized earnings of FY26. The company is seeking a total market capitalization of ₹174.79 crore at the higher price limit. The price to book value ratio is 7.46 based on the net asset value of ₹18.64 per share. The post-issue net asset value stands at ₹51.14 per share at the upper price band.

IPO Objective

The company will use the proceeds of the offer to meet stated objectives:

₹28.50 crore for capital expenditure on setting up of new manufacturing facility at the existing premises
₹6.50 crore for repayment or prepayment of certain borrowings
Remaining funds for general corporate purposes

Promoters & Lead Manager

Mr. Mukesh Mehta has deep pharmaceutical industry expertise.
Mr. Pradeep Mehta leads the execution teams effectively.
Narnolia Financial Services Ltd. manages the public issue. They managed 10 listings in its recent track record. Two previous public issues listed at a discount price on the stock exchange. The remaining public issues listed with a premium between 19.23% and 90% on the listing day.

Peer Comparison

Below is the comparison of the company with its listed peers using data from March 31, 2025. These companies are not truly comparable.

Company Name	EPS (Basic)	NAV (₹ per share)	P/E (x)	RoNW (%)	P/BV Ratio
Bio Medica Laboratories Ltd.	10.67	16.05		99.59
Zenotech Laboratories Limited	0.92	15.76		6.01	4.13
Shukra Pharmaceuticals Limited	0.22	1.43	47.57	15.9	20

Financial data sourced from annual reports and stock exchange data, using restated financial statements for 2024-25. NAV per share (closing net worth divided by weighted average number of paid-up equity shares) and RoNW (net profit after tax divided by closing net worth).

IPO Review & Analyst Rating

The company manufactures pharmaceutical parenteral formulations like liquid injections and dry powder injections. It operates on a B2B contract manufacturing model for other pharmaceutical companies. The business does not deal directly with end users. It holds valid certificates for good manufacturing practices and good laboratory practices in Madhya Pradesh. The workforce consists of 56 employees on its payroll. The financial data shows a sudden spike in margins from FY25 onward. The debt equity ratio stands high at 2.23 as of November 30, 2025. The lead manager has managed 29 mandates in the last four fiscal years. The issue seems to be priced aggressively when we look at the boosted financial data, which is questionable due to its extreme competitive market type.

Analyst Name	Recommendation
Univest	Neutral
MNCL Group Research	Neutral

Disclaimer: The information on the site is informational only. The contents of this blog are not financial advice. You should not invest in any stock market instrument without consulting your Financial advisor.

Sanjay Bambhaniya

Sanjay has 8+ years of experience in data-driven IPO insights. His expertise in digital marketing and web development complements his financial knowledge and helps him to develop effective fintech solutions. He is an entrepreneur and director who helps investors understand complex primary market trends in easy-to-understand IPO reports, news, and updates.

Discussion & Feedback

0 Comments

No comments yet. Be the first to share your thoughts!